These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 35420638)

  • 1. Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.
    Momozawa Y; Sasai R; Usui Y; Shiraishi K; Iwasaki Y; Taniyama Y; Parsons MT; Mizukami K; Sekine Y; Hirata M; Kamatani Y; Endo M; Inai C; Takata S; Ito H; Kohno T; Matsuda K; Nakamura S; Sugano K; Yoshida T; Nakagawa H; Matsuo K; Murakami Y; Spurdle AB; Kubo M
    JAMA Oncol; 2022 Jun; 8(6):871-878. PubMed ID: 35420638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic
    Alenezi WM; Fierheller CT; Revil T; Serruya C; Mes-Masson AM; Foulkes WD; Provencher D; El Haffaf Z; Ragoussis J; Tonin PN
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
    Silvestri V; Leslie G; Barnes DR; ; Agnarsson BA; Aittomäki K; Alducci E; Andrulis IL; Barkardottir RB; Barroso A; Barrowdale D; Benitez J; Bonanni B; Borg A; Buys SS; Caldés T; Caligo MA; Capalbo C; Campbell I; Chung WK; Claes KBM; Colonna SV; Cortesi L; Couch FJ; de la Hoya M; Diez O; Ding YC; Domchek S; Easton DF; Ejlertsen B; Engel C; Evans DG; Feliubadalò L; Foretova L; Fostira F; Géczi L; Gerdes AM; Glendon G; Godwin AK; Goldgar DE; Hahnen E; Hogervorst FBL; Hopper JL; Hulick PJ; Isaacs C; Izquierdo A; James PA; Janavicius R; Jensen UB; John EM; Joseph V; Konstantopoulou I; Kurian AW; Kwong A; Landucci E; Lesueur F; Loud JT; Machackova E; Mai PL; Majidzadeh-A K; Manoukian S; Montagna M; Moserle L; Mulligan AM; Nathanson KL; Nevanlinna H; Ngeow J; Nikitina-Zake L; Offit K; Olah E; Olopade OI; Osorio A; Papi L; Park SK; Pedersen IS; Perez-Segura P; Petersen AH; Pinto P; Porfirio B; Pujana MA; Radice P; Rantala J; Rashid MU; Rosenzweig B; Rossing M; Santamariña M; Schmutzler RK; Senter L; Simard J; Singer CF; Solano AR; Southey MC; Steele L; Steinsnyder Z; Stoppa-Lyonnet D; Tan YY; Teixeira MR; Teo SH; Terry MB; Thomassen M; Toland AE; Torres-Esquius S; Tung N; van Asperen CJ; Vega A; Viel A; Vierstraete J; Wappenschmidt B; Weitzel JN; Wieme G; Yoon SY; Zorn KK; McGuffog L; Parsons MT; Hamann U; Greene MH; Kirk JA; Neuhausen SL; Rebbeck TR; Tischkowitz M; Chenevix-Trench G; Antoniou AC; Friedman E; Ottini L
    JAMA Oncol; 2020 Aug; 6(8):1218-1230. PubMed ID: 32614418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
    Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
    JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
    Johansson PA; Nathan V; Bourke LM; Palmer JM; Zhang T; Symmons J; Howlie M; Patch AM; Read J; Holland EA; Schmid H; Warrier S; Glasson W; Höiom V; Wadt K; Jönsson G; Olsson H; Ingvar C; Mann G; Brown KM; Hayward NK; Pritchard AL
    Melanoma Res; 2019 Oct; 29(5):483-490. PubMed ID: 31464824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
    Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
    J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
    PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
    Azribi F; Abdou E; Dawoud E; Ashour M; Kamal A; Al Sayed M; Burney I
    BMC Cancer; 2021 Dec; 21(1):1350. PubMed ID: 34930165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
    BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.
    Valarmathi MT; Sawhney M; Deo SSV; Shukla NK; Das SN
    Hum Mutat; 2004 Feb; 23(2):205. PubMed ID: 14722926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients.
    Zhang Y; Wu H; Gan C; Rao H; Wang Q; Guo X
    BMC Med Genomics; 2024 Jan; 17(1):3. PubMed ID: 38167124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.
    Abul-Husn NS; Soper ER; Odgis JA; Cullina S; Bobo D; Moscati A; Rodriguez JE; ; ; Loos RJF; Cho JH; Belbin GM; Suckiel SA; Kenny EE
    Genome Med; 2019 Dec; 12(1):2. PubMed ID: 31892343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Recurrent Variants in
    Jiang Y; Tian T; Yu C; Zhou W; Yang J; Wang Y; Wen Y; Chen J; Dai J; Jin G; Ma H; Shen H; Hu Z
    Biomed Res Int; 2020; 2020():6739823. PubMed ID: 32879886
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.